31
Mar, 2020
Leading the world in
early cancer detection research
Our innovative cancer screening
studies mean better outcomes for patients
Innovation in cancer research
and development
We are changing the face of cancer detection
and treatment using the latest
advancements in Metabolomics
Non-invasive and affordable early
cancer
screening and monitoring
solution
90% of cancers are curable if caught early
Your Health is Our Focus!
BIOMARK’S MISSION
To provide universal access to a new paradigm in cancer diagnostics using metabolomics.
WHAT IS A BIOMARKER?
According to the National Cancer Institute a biomarker is “a biological molecule found in blood, other body fluids or tissues that is a sign of a normal or abnormal process or of a condition or disease” (NCI) such as cancer.
Biomarkers typically differentiate an affected patient from a person without the disease. There is tremendous variety of biomarkers which can include:
- proteins (e.g. an enzyme or receptor)
- nucleic acids (e.g. a microRNA or other non-coding RNA)
- antibodies
- and peptides among other categories
A biomarker can also be a collection of alterations such as gene expression, proteomic, and metabolomic signatures.
Biomarkers can be detected in the circulation (whole blood, serum, or plasma) or excretions or secretions (stool, urine, sputum, or nipple discharge) and thus easily assessed non-invasively and serially. Biomarkers can also be tissue-derived and require either biopsy or special imaging for evaluation.
Sign up to learn about new research and developments from BioMark
POTENTIAL CLINICAL USES OF CANCER BIOMARKERS
Biomarkers have many potential applications in oncology including:
- Estimating risk of cancer
- Screening for occult primary cancers
- Distinguishing benign from malignant findings or one type of malignancy from another
- Monitoring status of the disease either to detect recurrence or determine response or progression to therapy
- Personalizing a treatment program especially for immunotherapy applications
- Help in assessing pseudo progression with imaging modalities
LATEST NEWS
19
Aug, 2019
BIOMARK’S LIQUID BIOPSY SCIENTIFIC PAPER TO BE FEATURED AS COVER ON CANCERS UPCOMING ISSUE
Vancouver, British Columbia – (August 19th, 2019) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “Liquid Biopsy in Lung Cancer Screening: The Contribution of Metabolomics. Results of A Pilot Study” will be on cover of Cancers. Rashid Ahmed, President and CEO, says, “This latest paper that was published a few days ago paper has been selected by the editors of…
READ MORENEWS RELEASES
BIOMARK’S LIQUID BIOPSY ASSAY LEVERING METABOLOMICS DEMONSTRATES STRONG PERFORMANCE FOR EARLY LUNG CANCER DETECTION
March 24, 2020
Vancouver, British Columbia – ( March 24th, 2020) – BioMark Diagnostics Inc. (“BioMark”) (CSE: BUX) (FSE: 20B) (OTCMKTS: BMKDF) is pleased to announce that the article “A High-Performing Plasma Metabolite Panel for Early-Stage Lung Cancer Detection” has been published in the peer-reviewed journal Cancers, validating BioMark’s technology to detect early-stage (I/II) non-small cell lung cancer (NSCLC) using a simple blood plasma test. Rashid Bux, President and CEO, says, “This latest publication demonstrates our ability to further leverage our international team of leading clinicians, scientists, researchers and data scientists in discovery […]
READ MORE
STOCK QUOTE
BIOMARK AWARDS, GRANTS, RECOGNITIONS
BioMark has been over the years, funded by various government agencies and Foundation including NRC IRAP, NRC Engage, Genome BC, Government of Manitoba and DFAIT Canada for various projects with active collaboration at University of British Columbia, University of Manitoba, University of Victoria, University of Waterloo, and University of Alberta. Now BioMark is collaborating with Bio banks across Canada and United States to expand our metabolomics study.